Statin myopathy as a metabolic muscle disease

References

• Dykens JA, Will Y. The significance of mitochondrial toxicity testing in drug development. Drug Discov. Today12, 777–785 (2007).
   PubMed Web of Science ®Google Scholar
• Lofberg M, Jankala H, Paetau A, Harkonen M, Somer H. Metabolic causes of recurrent rhabdomyolysis. Acta Neurol. Scand.98, 268–275 (1998).
   PubMedGoogle Scholar
• Vladutiu GD, Simmons Z, Isackson PJ et al. Genetic risk factors associated with lipid-lowering drug-induced myopathies. Muscle Nerve34, 153–162 (2006).
   PubMed Web of Science ®Google Scholar
• Bank WJ, DiMauro S, Bonilla E, Capuzzi DM, Rowland LP. A disorder of muscle lipid metabolism and myoglobinuria. Absence of carnitine palmityl transferase. N. Engl. J. Med.292, 443–449 (1975).
   PubMed Web of Science ®Google Scholar
• Kaufmann P, Török M, Zahno A, Waldhauser KM, Brecht K, Krähenbühl S. Toxicity of statins on rat skeletal muscle mitochondria. Cell Mol. Life Sci.63, 2415–2425 (2006).
   PubMed Web of Science ®Google Scholar
• Wagner BK, Kitami T, Gilbert TJ et al. Large-scale chemical dissection of mitochondrial function. Nat. Biotechnol.26, 343–351 (2008).
   PubMed Web of Science ®Google Scholar
• Velho JA, Okanobo H, Degasperi GR et al. Statins induce calcium-dependent mitochondrial permeability transition. Toxicology219, 124–132 (2006).
   PubMed Web of Science ®Google Scholar
• Hanai J, Cao P, Taksale P et al. The muscle-specific ubiquitin ligase, atrogin-1/MAFbx mediates toxicity from HMG CoA reductase inhibitors. J. Clin. Invest.117, 3940–3951 (2007).
   PubMed Web of Science ®Google Scholar
• Phillips PS, Haas RH, Barshop B, Bannykh S, Amjadi D. Utility of abnormal 3-methylglutaconic aciduria (3MGA) in diagnosing statin associated myopathy. [abstract]. Atheroscler. Thromb. Vasc. Biol.22, 878 (2002).
   Google Scholar
• Phillips PS, Haas RH, Bannykh S et al.; The Scripps Mercy Clinical Research Center. Statin associated myopathy with normal creatine kinase. Ann. Int. Med.137, 581–585 (2002).
   PubMed Web of Science ®Google Scholar
• Truong TH, Moran, R, Laaksonen R et al. Muscle characteristics in statin myotoxicity. J. Am. Coll. Cardiol.51, A326 (2008) (Abstract).
   Google Scholar
• Paiva H, Thelen KM, Van CR et al. High-dose statins and skeletal muscle metabolism in humans: a randomized, controlled trial. Clin. Pharmacol. Ther.78, 60–68 (2005).
   PubMed Web of Science ®Google Scholar
• Schick BA, Laaksonen R, Frohlich JJ et al. Decreased skeletal muscle mitochondrial DNA in patients treated with high-dose simvastatin. Clin. Pharmacol. Ther.81, 650–653 (2007).
   PubMed Web of Science ®Google Scholar
• Scheller K, Seibel P, Sekeris CE. Glucocorticoid and thyroid hormone receptors in mitochondria of animal cells. Int. Rev. Cyt.222, 1–61 (2003).
   PubMed Web of Science ®Google Scholar
• Duntas LH. Review – thyroid disease and lipids. Thyroid12, 287–293 (2002).
   PubMed Web of Science ®Google Scholar
• Kordas KC, Phillips PS, Golomb BA. Clinical characteristics of 1053 patients with statin associated muscle complaints. Artheroscler. Thromb. Vasc. Biol.24, E51–E136 (2004) (Abstract).
   Google Scholar
• Jagoe RT, Goldberg AL. What do we really know about the ubiquitin-proteasome pathway in muscle atrophy? Curr. Opin. Clin. Nutr. Metab. Care.4, 183–190 (2001).
   PubMed Web of Science ®Google Scholar
• Gomes MD, Lecker SH, Jagoe RT, Navon A, Goldberg AL. Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy. Proc. Natl Acad. Sci. USA98, 14440–14445 (2001).
   PubMed Web of Science ®Google Scholar
• Phillips PS, Phillips CT, Sullivan M, Naviaux RK, Haas RH and the Scripps Mercy Clinical Research Center. Statin myotoxicity is associated with changes in cardiopulmonary function. Atherosclerosis177, 183–188 (2004).
   PubMed Web of Science ®Google Scholar
• Westwood FR, Bigley A, Randall K, Marsden AM, Scott RC. Statin-induced muscle necrosis in the rat: distribution, development, and fibre selectivity. Toxicol. Path.33, 246–257 (2005).
   PubMed Web of Science ®Google Scholar
• Thompson PD, Nugent AM, Herbert PN. Increases in creatine kinase after exercise in patients treated with HMG Co-A reductase inhibitors. JAMA264, 2992 (1990).
   PubMedGoogle Scholar
• Franc S, Dejager S, Bruckert E, Chauvenet M, Giral P, Turpin G. A comprehensive description of muscle symptoms associated with lipid-lowering drugs. Cardiovasc. Drugs Ther.17, 459–465 (2003).
   PubMed Web of Science ®Google Scholar
• Sinzinger H, O’Grady J. Professional athletes suffering from familial hypercholesterolaemia rarely tolerate statin treatment because of muscular problems. Br. J. Clin. Pharmacol.57, 525–528 (2004).
   PubMed Web of Science ®Google Scholar
• Urso ML, Clarkson PM, Hittel D, Hoffman EP, Thompson PD. Changes in ubiquitin proteasome pathway gene expression in skeletal muscle with exercise and statins. Aterioscler. Thromb. Vasc. Biol.25, 2560–2566 (2005).
   PubMed Web of Science ®Google Scholar
• Paolisso G, Barbagallo M, Petrella G et al. Effects of simvastatin and atorvastatin administration on insulin resistance and respiratory quotient in aged dyslipidemic non-insulin dependent diabetic patients. Atherosclerosis150, 121–127 (2000).
   PubMed Web of Science ®Google Scholar
• Moran R, Truong T, Wolfson T, McDonald FG, Phillips PS. Utility of cardiopulmonary exercise to assess myopathy [abstract]. Arterioscler. Thromb. Vasc. Biol. (2008) (In Press).
   Google Scholar
• Barker BJ, Goodenough RR, Falko JM. Fenofibrate monotherapy induced rhabdomyolysis. Diabetes Care26, 2482–2483 (2003).
   PubMedGoogle Scholar
• Litin SC, Anderson CF. Nicotinic acid-associated myopathy: a report of three cases. Am. J. Med.86, 481–483 (1989).
   PubMed Web of Science ®Google Scholar
• Havranek JM, Wolfsen A, Warnke GA, Philips PS. Monotherapy with ezetimibe causing myopathy. Am. J. Med.119, 285–286 (2006).
   PubMed Web of Science ®Google Scholar
• Durst R, Rund D, Schurr D et al. One year experience with a low density lipoprotein apheresis system. IMAJ4, 677–680 (2002).
   Google Scholar
• Sikand H, Jaojoco J, Linares L, Phillips PS. Risk of death with atypical antipsychotics [letter]. JAMA295, 495–496 (2006).
   PubMedGoogle Scholar
• Lieber CS, Leo MA, Xiaolei W, DeCarli LM. Effect of chronic alcohol consumption on hepatic SIRT1 and PGC-1a in rats. Biochem. Biophys. Res. Com.370, 44–48 (2008).
   PubMedGoogle Scholar
• Cade WT, Reeds DN, Mittendorfer B et al. Blunted lipolysis and fatty acid oxidation during moderate exercise in HIV-infected subjects taking HAART. Am. J. Physiol. Endocrinol. Metab.292, E812–E819 (2007).
   PubMed Web of Science ®Google Scholar
• Luzi L, Perseghin G, Tambussi G et al. Intramyocellular lipid accumulation and reduced whole body lipid oxidation in HIV lipodystrophy. Am. J. Physiol. Endocrinol. Metab.284, E274–E280 (2003).
   PubMed Web of Science ®Google Scholar
• Gaist D, Garcia Rodriguez LA, Huerta C, Hallas J, Sindrup SH. Lipid-lowering drugs and risk of myopathy: a population-based follow-up study. Epidemiology12, 565–569 (2001).
   PubMed Web of Science ®Google Scholar
• Graham DJ, Staffa JA, Shatin D et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA292, 2585–2590 (2004).
   PubMed Web of Science ®Google Scholar
• Castro Cabezas M, de Bruin TW, de Valk HW et al. Impaired fatty acid metabolism in familial combined hyperlipidemia. A mechanism associating hepatic apolipoprotein B overproduction and insulin resistance. J. Clin. Invest.92, 160–168 (1993).
   PubMedGoogle Scholar
• Phillips PS, Ciaraldi TP, Kim DL, Verity MA, Wolfen AR, Henry RR. Myotoxic reactions to lipid-lowering therapy are associated with altered oxidation of fatty acids [abstract]. J. Am. Coll. Cardiol.45, 413A (2005).
   Google Scholar
• Edwards IR, Star K, Kiuru A. Statins, neuromuscular degenerative disease and an amyotrophic lateral sclerosis-like syndrome: an analysis of individual case safety reports from vigibase. Drug Saf.30, 515–525 (2007).
   PubMed Web of Science ®Google Scholar
• Dupuis L, Oudart H, René F, Gonzalez de Aguilar JL, Loeffler JP. Evidence for defective energy homeostasis in amyotrophic lateral sclerosis: benefit of a high-energy diet in a transgenic mouse model. Proc. Natl Acad. Sci. USA101, 11159–11164 (2004).
   PubMed Web of Science ®Google Scholar
• Fergani A, Oudart H, Gonzalez De Aguilar JL et al. Increased peripheral lipid clearance in an animal model of amyotrophic lateral sclerosis. J. Lipid Res.48, 1571–1580 (2007).
   PubMed Web of Science ®Google Scholar
• Glass DJ. Skeletal muscle hypertrophy and atrophy signaling pathways. Int. J. Biochem. Cell Biol.37, 1974–1984 (2005).
   PubMed Web of Science ®Google Scholar
• Iakoubova OA, Tong CH, Rowland CM et al. Association of the Trp719Arg polymorphism in kinesin-like protein 6 with myocardial infarction and coronary heart disease in 2 prospective trials: the CARE and WOSCOPS trials. J. Am. Coll. Cardiol.51, 435–443 (2008).
   PubMed Web of Science ®Google Scholar
• Iakoubova OA, Sabatine MS, Rowland CM et al. Polymorphism in KIF6 gene and benefit from statins after acute coronary syndromes: results from the PROVE IT-TIMI 22 study. J. Am. Coll. Cardiol.51, 449–455 (2008).
   PubMed Web of Science ®Google Scholar